NextCure Inc
Company Profile
Business description
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer’s disease.
Contact
9000 Virginia Manor Road
Suite 200
BeltsvilleMD20705
USAT: +1 240 399-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
43
Stocks News & Analysis
stocks
After slump this ASX share may be an opportunity
stocks
Investment decisions in overvalued bank drive strong results
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,098.40 | 53.80 | -0.59% |
| CAC 40 | 8,101.23 | 45.72 | 0.57% |
| DAX 40 | 23,989.85 | 29.86 | 0.12% |
| Dow JONES (US) | 47,368.63 | 381.53 | 0.81% |
| FTSE 100 | 9,888.14 | 100.99 | 1.03% |
| HKSE | 26,696.41 | 47.35 | 0.18% |
| NASDAQ | 23,527.17 | 522.64 | 2.27% |
| Nikkei 225 | 50,842.93 | 68.83 | -0.14% |
| NZX 50 Index | 13,604.55 | 12.93 | -0.09% |
| S&P 500 | 6,832.43 | 103.63 | 1.54% |
| S&P/ASX 200 | 8,818.80 | 56.80 | -0.64% |
| SSE Composite Index | 4,002.76 | 15.84 | -0.39% |